EP1513846A1 - Verfahren zur herstellung von olanzapine forme i - Google Patents

Verfahren zur herstellung von olanzapine forme i

Info

Publication number
EP1513846A1
EP1513846A1 EP03736771A EP03736771A EP1513846A1 EP 1513846 A1 EP1513846 A1 EP 1513846A1 EP 03736771 A EP03736771 A EP 03736771A EP 03736771 A EP03736771 A EP 03736771A EP 1513846 A1 EP1513846 A1 EP 1513846A1
Authority
EP
European Patent Office
Prior art keywords
olanzapine
toluene
olanzapine form
solvent
dichloromethane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP03736771A
Other languages
English (en)
French (fr)
Other versions
EP1513846B1 (de
Inventor
Hiren V. Patel
Anup K. Ray
Pramod B. Patel
Mahendra R. Patel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Original Assignee
Sandoz AG
Sandoz Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz AG, Sandoz Inc filed Critical Sandoz AG
Priority to SI200332002T priority Critical patent/SI1513846T1/sl
Publication of EP1513846A1 publication Critical patent/EP1513846A1/de
Application granted granted Critical
Publication of EP1513846B1 publication Critical patent/EP1513846B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Definitions

  • the compound 2-methyl-4-(4-methyl-1 -piperazinyl)-10H-thieno[2,3-b] [1 ,5]benzodiazepine is named olanzapine according to the U.S.A.N. It is known as an anti- psychotic agent.
  • Form I of 2-methyl-4-(4-methyl-1-piperazinyl)-10H- thieno[2,3-b][1 ,5] benzodiazepine, having m.p. 195°C, is used in pharmaceutical formulations.
  • a process to prepare olanzapine is disclosed in U.S. Patent 5,229,382, which is incorporated herein by reference.
  • the last step of the reaction disclosed in the patent comprises mixing 4-amino-2- methyl-10H-thieno[2,3-b][1 ,5]benzodiazepine and 4-methylpiperazine and refluxing in a suitable organic solvent to yield the desired Form I. It has been found that olanzapine prepared according to the process of the '382 patent is contaminated with olanzapine Form II as an impurity. Accordingly there is a need for a process to prepare olanzapine Form I free of the Form II impurity.
  • the present invention provides a process to prepare olanzapine Form I free from impurity with Form II.
  • the present invention provides an improvement to the process of the prior art. This improvement is in the purification and separation of olanzapine Form I from the reaction mixture by the application of a different pH in its solution state with different organic solvents. This technique yields very stable pure anhydrous polymorphic Form I which is free of other polymorphs and solvating agents such as water and organic solvents.
  • Form I olanzapine prepared by the process of the present invention also has satisfactory color and thermal stability for use in a pharmaceutical solid dosage form.
  • the process of the present invention is environmentally friendly and can be applied in large scale, e.g. on the kg level, for commercial manufacturing of olanzapine Form I.
  • Figure 1 is the FT-IR spectrum of olanzapine Form I prepared according to the present invention.
  • Figure 2 is the FT-IR spectrum of Form I olanzapine prepared according to the present invention and olanzapine Form II standard.
  • the present invention is directed to a process for producing olanzapine Forml, which comprises reacting N-methylpiperazine and a compound of formula I:
  • the radical Q can, for example, be an amino group or a mono- or dialkyl-substituted amino group (each alkyl substituent containing 1 to 4 carbon atoms), hydroxyl, thiol, or an alkoxy, alkylthio, or alkylsulphonyl group containing 1 to 4 carbon atoms, such as methoxy or methylthio, or a halogen, such as chlorine.
  • Q is amino (-NH 2 ), hydroxyl, or thiol, amino being preferred.
  • the amidine of formula I, where Q is -NH 2 can be in a salt form, for example a salt of a mineral acid such as the hydrochloride.
  • the reaction is carried out in the presence of an aprotic high boiling solvent, preferably anhydrous dimethyl sulfoxide, at a temperature of 50°C to 200°C, or 90°C to 130°C, or from 115°C to 120°C, or around 110°C.
  • the aprotic solvent preferably anhydrous, may be dimethyl sulfoxide, dimethyformamide, or mixtures of either of these with toluene.
  • the resulting olanzapine is purified in an acidic medium followed by extraction with organic solvents.
  • the acidic medium for the purification step can be prepared with an organic acid, preferably 40-60% acetic acid.
  • the resulting mixture is then basified (pH 7.5- 9.0) under cold conditions, 0°C to 10°C, preferably to a pH of 7.5-8.5, using an inorganic base such as sodium hydroxide, potassium hydroxide or lithium hydroxide.
  • Sodium hydroxide is the preferred agent. More preferably 30-60% aqueous sodium hydroxide is used.
  • the mixture is subject to extraction using a low boiling organic solvent such as diethylether, dichloromethane, dichloroethane, chloroform, ethyl acetate, or other low polar ketonic solvents.
  • the solvent is dichloromethane.
  • Base solvent refers to the solvent state that results from the combination of an inorganic base and a high boiling solvent.
  • high boiling solvents include toluene, methyl ethyl ketone, and acetonitrile. Toluene is most preferred.
  • the basic solvent comprises toluene and alcoholic sodium hydroxide. Examples of alcohols include methanol, ethanol. and isopropanol, with methanol being most preferred.
  • the most preferred basic solvent is toluene and methanolic sodium hydroxide.
  • the solution prior to extraction, the solution is made basic to a pH of about 7.5-9.0 using aqueous sodium hydroxide. With the solution in this basic state, extraction is done with dichloromethane. Each extraction step produces an aqueous phase and a dichloromethane phase. After washings and extraction, the residual dichloromethane is completely removed by rotary evaporation since it can cause conversion to olanzapine Form II. After removal of the dichloromethane, a high boiling solvent, such as toluene, and a basic solvent such as methanolic NaOH are added.
  • a high boiling solvent such as toluene
  • a basic solvent such as methanolic NaOH
  • pure olanzapineForml can be crystallized from the basic solvent state by seeding. Crystallization is preferably accomplished at 0°C to 30°C.
  • the prior art method used toluene as solvent. However, toluene alone also results in some Form II contamination. By the addition of toluene in a basic state only polymorph Form I is obtained.
  • the reaction mixture is extracted using a low boiling point solvent with good solubility, preferably dichloromethane, prior to basifying, to pH 7.5-9.0, as discussed above.
  • a low boiling point solvent with good solubility preferably dichloromethane
  • ultra-pure olanzapine Form I i.e., olanzapine Form I substantially free of other polymorphic forms of olanzapine; in particular, free of olanzapine Form II.
  • substantially free is meant 98-100%, preferably at least 99%, free of other polymorphic forms.
  • Another embodiment of the invention is a pharmaceutical composition
  • a pharmaceutical composition comprising ultra-pure olanzapine Form I and a pharmaceutically acceptable diluent or carrier therefor.
  • Another embodiment of the invention is a method of treating a person in need thereof, e.g., someone suffering from or susceptible to psychosis, acute mania, or mild anxiety states, which comprises administering to said person an effective amount of ultra- pure olanzapine Form I.
  • the reaction mixture is stirred at 112-115°C (oil bath temperature 115°C) for 16 hours under continuous flow of nitrogen to drive away the ammonia gas generated during the reaction.
  • the reaction is monitored by HPLC and it is found that within 16 hours 97% product is formed.
  • the reaction mixture is cooled to room temperature (24- 25°C) and added dropwise to a mixture of dichloromethane.water-methanol (190:190:15, 395 mL). After addition, the reaction mixture is stirred for 30 minutes at room temperature. The resulting mixture is yellowish hazy with a dark brown organic layer settled at the bottom of the flask. The dark brown colored dichloromethane layer is separated from the aqueous hazy phase.
  • aqueous hazy phase is again extracted with dichloromethane (1x100.0 mL).
  • the combined dichloromethane phases (total volume 290.0 mL) are extracted twice with 50 % aqueous acetic acid solution (1x100 mL, 1x75.0 mL). A dark orange color acetic acid layer is separated.
  • the pH of the acetic acid solution is found to be around 3.0-3.5 when tested by litmus paper.
  • Combined aqueous acetic acid solution is basified, to pH 7.5-8.5, using 40% aqueous sodium hydroxide solution under cold conditions (0-10°C). After attaining the desired pH of the solution, 200 mL dichloromethane is added and stirred.
  • the content is transferred to a separating funnel and is vigorously shaken.
  • the dichloromethane layer is separated and the aqueous phase is again extracted with dichloromethane (1x75.0 mL).
  • the combined dichloromethane extracts are washed with cold saturated sodium chloride solution (1x30.0 mL) and dried over anhydrous sodium sulfate. Removal of solvent on a rotary evaporator with a water bath temperature of 45°C, gives a dark orange brown viscous liquid. To this viscous liquid, 80-85.0 mL dry toluene is added.
  • the toluene containing crude olanzapine is transferred into a dry 250 mL single necked round bottom flask.
  • Methanolic sodium hydroxide solution (0.32 g sodium hydroxide dissolved in 3.0-4.0 mL methanol by sonication) is added and the mixture is heated in an oil bath at 60°C for 2 hours.
  • 20-25 % of the total volume of solvent is evaporated on a rotary evaporator, with a 55-60°C water bath, to ensure the complete removal of dichloromethane and trace amounts of water, resulting in a final volume of between 55-60 mL.
  • the hot solution is removed from the water bath and cooled in an ice bath with stirring.
  • HPLC conditions are as follows: Column: SymmetryC 18 , 4.6 x 250 mm ⁇ max 254 nm
  • the buffer comprises 5.4 g potassium phosphate; 0.5 g heptanesulfonic acid sodium salt and 0.5 g 1-octanesulfonic acid sodium salt dissolved in 500 mL Dl water and adjusted the pH to 2.6 using cone, phosphoric acid.
  • the mobile phase was 500 mL buffer/300 mL acetonitrile/200 mL methanol.
  • the final pH of the mobile phase is about 3.6.
  • Olanzapine Form I prepared according to Example 1 is analyzed by X-ray, IR, and DSC and found to conform to a commercially available reference standard olanzapine Form I.
  • DSC of the olanzapine Form I prepared according to the present invention shows an endotherm peak at 195°C.
  • the X-ray powder diffractometry (XRD) study of olanzapine Form I and Form II is done in the following manner.
  • the polymorph powder is filled into an aluminum holder and exposed to CuK ⁇ radiation (40 kV x 30 mA) in a wide range X-ray powder diffractometer (Model D5005, Siemens).
  • the instrument is operated in the step-scan mode, in increments of 0.02° 2 ⁇ .
  • the angular range is 5 to 50° 2 ⁇ and counts are accumulated for 1 second at each step.
  • a typical x-ray diffraction pattern for Form I is as follows, wherein d represents the interplanar spacing and l/l 0 represents the typical relative intensities. In the following tables (olanzapine Form I and Form II ) only those peaks are listed whose relative intensity l/lo is equal or greater than 10%.
  • a typical example of an X-ray diffraction pattern for Form II is as follows, wherein d represents the interplanar spacing and l/l 0 (>10%) represents the typical relative intensities. Standard polymorph Form II was obtained from Neuland Laboratories, India.
  • Figure 2 shows Form II at a 3% level and a 5% level in Form I.
  • Reference standard polymorph Form I was obtained from Dr. Reddy's Laboratories and Form II from Neuland
  • the combined dichloromethane phase (290.0 mL) was extracted twice with 50 % aqueous acetic acid solution (1x100 mL, 1x75.0 mL). A dark orange color acetic acid layer was separated. The pH of the acetic acid solution was found to be around 3.0-3.5 (tested by litmus paper).
  • the combined aqueous acetic acid solution was basified using 40% aqueous sodium hydroxide solution under cold condition (0-10°C) to pH 7.5-8.0. (During the basification step, pH above 8.0 results in the appearance of solids.) After attaining the desired pH, dichloromethane was added (200 mL) and the solution was stirred.
  • the pH may be adjusted after the addition of dichloromethane in the aqueous acetic acid phase.
  • the content was transferred to a separating funnel and vigorously shaken.
  • the dichloromethane layer was separated and the aqueous phase was again extracted with dichloromethane (1x75.0 mL).
  • the combined dichloromethane extract was washed with cold saturated sodium chloride solution (1x30.0 mL) and dried over anhydrous sodium sulfate. While drying, the solution with sodium sulfate is shaken vigorously up and down in order to remove the water efficiently.
  • Removal of solvent on rotary evaporator water bath temperature 45°C gave a dark orange brown viscous liquid with 10-15 % total dichloromethane.
  • the solution was stirred for 30-35 minutes at 0- 10°C temperature.
  • the yellowish solid obtained was filtered on a vacuum pump and washed with a small quantity of dichloromethane (2.0-2.5 mL).
  • the solid was dried on a vacuum pump for 40-45 minutes.
  • the obtained solid was crushed into fine powder and air dried to remove all traces of dichloromethane and toluene.
  • the air dried material was dried in the oven at 65°C for 1.5-2.0 hours and analyzed for water content. Karl Fisher study showed 670-860 ppm water content.
  • the weight of the title product was 1.93 g (95.0 % crystallization yield) of 99.96 % HPLC purity.
  • X-ray, IR, DSC of the crystallized product conforms to reference standard olanzapine Form I and equivalent to the results of the solid obtained in first crystallization (as is).
  • FT-IR shows apparently 100% polymorphic purity when compared with 2% standard addition technique of Form II with Form I.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP03736771A 2002-05-31 2003-05-30 Verfahren zur herstellung von olanzapin form i Expired - Lifetime EP1513846B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SI200332002T SI1513846T1 (sl) 2002-05-31 2003-05-30 Postopek za pripravo olanzapina form I

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16095802A 2002-05-31 2002-05-31
US160958 2002-05-31
PCT/US2003/017186 WO2003101997A1 (en) 2002-05-31 2003-05-30 Process of preparation of olanzapine form i

Publications (2)

Publication Number Publication Date
EP1513846A1 true EP1513846A1 (de) 2005-03-16
EP1513846B1 EP1513846B1 (de) 2011-03-02

Family

ID=29709737

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03736771A Expired - Lifetime EP1513846B1 (de) 2002-05-31 2003-05-30 Verfahren zur herstellung von olanzapin form i

Country Status (7)

Country Link
US (2) US7297789B2 (de)
EP (1) EP1513846B1 (de)
AT (1) ATE500258T1 (de)
AU (1) AU2003237305A1 (de)
DE (1) DE60336226D1 (de)
SI (1) SI1513846T1 (de)
WO (1) WO2003101997A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109456336A (zh) * 2017-09-06 2019-03-12 万全万特制药江苏有限公司 奥氮平的精制方法

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL202856B1 (pl) * 2002-12-20 2009-07-31 Adamed Spo & Lstrok Ka Z Ogran Sposób otrzymywania farmaceutycznie czystej polimorficznej postaci I olanzapiny
WO2004058773A1 (en) * 2002-12-24 2004-07-15 Teva Pharmaceutical Industries Ltd. Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms
EP1611139B1 (de) * 2003-12-22 2008-06-04 Teva Pharmaceutical Industries Ltd. Verfahren zur herstellung von olanzapin
EP1711503A1 (de) * 2004-01-27 2006-10-18 Synthon B.V. Synthese von olanzapin und zwischenprodukten davon
WO2005070938A1 (en) 2004-01-27 2005-08-04 Synthon B.V. Stable salts of olanzapine
AR048272A1 (es) * 2004-03-18 2006-04-12 Lek Pharmaceuticals Sintesis de 2 metil - 4- (4- metil -1- piperazinil) - 10 h- tieno ( 2,3-b) (1,5) benzodiazepina y sus sales, metodos para su preparacion, composiciones farmaceuticas que la contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mentales.
US8044196B2 (en) * 2004-07-14 2011-10-25 Jubilant Organosys Limited Process for producing pure form of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine
ES2253091B1 (es) 2004-07-27 2007-02-01 Inke, S.A. Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo.
SI21850A (sl) * 2004-07-28 2006-02-28 Krka, Tovarna Zdravil, D.D., Novo Mesto Soli olanzapina in njihova pretvorba v prosto bazo olanzapina
ES2303462B1 (es) * 2004-09-06 2009-06-05 Shasun Chemicals And Drugs Limited Nuevo procedimiento para la preparacion de una forma polimorfica i de olanzapina farmaceuticamente pura.
BRPI0608484E2 (pt) * 2005-03-21 2014-10-29 Reddys Lab Ltd Dr Processo de preparação da forma i cristalina de olanzapina
EP1919923A1 (de) * 2005-08-17 2008-05-14 Synthon B.V. Verfahren zur herstellung von olanzapin form i
HUP0501046A2 (en) 2005-11-11 2007-08-28 Egis Gyogyszergyar Nyilvanosan Process for the preparation of olanzapine
ES2279715B1 (es) 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. Formulacion oral de olanzapina.
US7834176B2 (en) * 2006-01-26 2010-11-16 Sandoz Ag Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E
WO2007138376A1 (en) * 2006-06-01 2007-12-06 Aurobindo Pharma Limited An improved process for preparing olanzapine form i
WO2007144901A1 (en) * 2006-06-12 2007-12-21 Jubilant Organosys Limited Process for stabilization of olanzapine polymorphic form i
PL381564A1 (pl) * 2007-01-22 2008-08-04 Koźluk Tomasz Nobilus Ent Sposób wytwarzania zasadniczo czystej odmiany polimorficznej I olanzapiny
CA2593407A1 (en) * 2007-06-22 2008-12-22 Apotex Pharmachem Inc. Improved processes for the synthesis of olanzapine
EP2292624A1 (de) 2009-07-20 2011-03-09 LEK Pharmaceuticals d.d. Olanzapinreinigungsverfahren
CN102268010A (zh) * 2011-06-17 2011-12-07 大连美罗大药厂 一种奥氮平的制备方法和精制方法
KR101489062B1 (ko) * 2013-03-28 2015-02-02 동아에스티 주식회사 고순도의 올란자핀 및 이의 결정형 ii의 제조방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003097650A1 (en) 2002-05-17 2003-11-27 Institut Farmaceutyczny Methods for preparation of olanzapine polymorphic form i
WO2007020080A1 (en) 2005-08-17 2007-02-22 Synthon B.V. A process for making olanzapine form i

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH554362A (de) 1970-07-30 1974-09-30 Spofa Vereinigte Pharma Werke Verfahren zur herstellung von neuen estern tricyklischer piperazinoalkanole.
US4115568A (en) 1974-11-26 1978-09-19 Lilly Industries Limited Thieno[3,2-b]-[1,5]benzodiazepines
US5229382A (en) 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
GB9009229D0 (en) 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
US5817656A (en) 1991-04-23 1998-10-06 Eli Lilly And Company Mental disorders
US5605897A (en) 1991-04-23 1997-02-25 Eli Lilly And Company 2-methyl-thieno-benzodiazepine
US5627178A (en) 1991-04-23 1997-05-06 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5817655A (en) 1991-04-23 1998-10-06 Eli Lilly And Company Methods of treatment using a thieno-benzodiazepine
US5817657A (en) 1991-04-23 1998-10-06 Eli Lilly And Company Psychoactive substance disorders
EG23659A (en) 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
CR5278A (es) 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
US5631250A (en) 1995-03-24 1997-05-20 Eli Lilly And Company Process and solvate of 2-methyl-thieno-benzodiazepine
US5637584A (en) 1995-03-24 1997-06-10 Eli Lilly And Company Solvate of olanzapine
EG24221A (en) 1995-03-24 2008-11-10 Lilly Co Eli Process for preparing olanzapine
ZA978515B (en) 1996-09-23 1999-03-23 Lilly Co Eli Intermediates and process for preparing olanzapine
BR9711541A (pt) 1996-09-23 1999-08-24 Lilly Co Eli Dihidrato d de olanzapina
EP1155696B1 (de) 1997-04-15 2004-03-03 Eli Lilly And Company Verwendung von Olanzapin zur Herstellung eines Arzneimittels zur Neuroprotektion
AU9583498A (en) 1997-09-30 1999-04-23 Eli Lilly And Company Method for treating sexual dysfunction
US7022698B2 (en) 1999-12-28 2006-04-04 U & I Pharmaceuticals, Ltd. Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof
US6348458B1 (en) 1999-12-28 2002-02-19 U & I Pharmaceuticals Ltd. Polymorphic forms of olanzapine
DK1246827T3 (da) 1999-12-28 2005-05-23 Cipla Ltd Nye polymorfe former af olanzapin
CZ2003566A3 (cs) 2000-08-31 2004-01-14 Dr. Reddy's Laboratories Ltd. Způsob přípravy hydrátů olanzapinu a jejich konverze na krystalické formy olanzapinu
US6740753B2 (en) 2001-01-04 2004-05-25 Geneva Pharmaceuticals, Inc. Olanzapine crystal modification
US20030097650A1 (en) * 2001-10-04 2003-05-22 International Business Machines Corporation Method and apparatus for testing software
CA2464306A1 (en) 2001-10-29 2003-05-08 Dr. Reddy's Laboratories Ltd. Olanzapine dihydrate-ii a process for its preparation and use thereof
AU2002367119A1 (en) 2001-12-24 2003-07-15 Sun Pharmaceutical Industries Limited Crystalline form I of 2-methyl-4-(4-methyl-1-piperazinyl) 10H thieno [2,3-b][1,5]benzodiazepine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003097650A1 (en) 2002-05-17 2003-11-27 Institut Farmaceutyczny Methods for preparation of olanzapine polymorphic form i
WO2007020080A1 (en) 2005-08-17 2007-02-22 Synthon B.V. A process for making olanzapine form i

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109456336A (zh) * 2017-09-06 2019-03-12 万全万特制药江苏有限公司 奥氮平的精制方法

Also Published As

Publication number Publication date
AU2003237305A1 (en) 2003-12-19
EP1513846B1 (de) 2011-03-02
US7297789B2 (en) 2007-11-20
US20040048854A1 (en) 2004-03-11
SI1513846T1 (sl) 2011-11-30
ATE500258T1 (de) 2011-03-15
US20080188465A1 (en) 2008-08-07
DE60336226D1 (de) 2011-04-14
WO2003101997A1 (en) 2003-12-11

Similar Documents

Publication Publication Date Title
US20080188465A1 (en) Process of Preparation of Olanzapine Form I
CN102993205B (zh) 一种高收率制备高纯度西地那非游离碱的纯化方法
Daunis et al. Heteroaromatic 10-. pi.-electron systems. New s-triazolo-as-triazines with a bridgehead nitrogen atom
EP1611139B1 (de) Verfahren zur herstellung von olanzapin
PL78658B1 (de)
US7776852B2 (en) Process for producing highly pure midazolam and salts thereof
RU2006136524A (ru) Синтез 2-метил-4-(4-метил-1-пиперазинил)-1oh-тиено(2, 3-в) (1,5)бензодиазепина и его солей
Xu et al. Reactions of 2, 3‐dihydro‐1H‐1, 5‐benzodiazepines and chloroacetyl chlorides: Synthesis of 2a, 3, 4, 5‐tetrahydro‐azeto [1, 2‐a][1, 5] benzodiazepin‐1 (2H)‐ones
CA2395774C (en) New polymorphic forms of olanzapine
CA2493370C (en) Crystal forms of olanzapine and processes for their preparation
WO2007087555A2 (en) Novel polymorph 'form e ' of olanzapine (2-methyl-4- (4-methyl-1-piperazinyl) -10h-thieno [2, 3-b] [1, 5] benzodiazepine) and preparation of the anhydrous non-solvated crystalline polymorphic 'form i' of olanzapine from the polymorphic olanzapine 'form e'
WO2006010620A2 (en) Olanzapine salts and their conversion to olanzapine free base
Anantanarayan et al. Synthesis of a dithia-18-crown-6-tetracarboxylic acid
SU847923A3 (ru) Способ получени 7 -/ -2-амино- 2-(Низший АлКилСульфОНилАМиНОфЕНил)- АцЕТилАМиНО/-3МЕТОКСи-3-цЕфЕМ-4- КАРбОНОВыХ КиСлОТ или иХ СОлЕй
EP0964861B1 (de) Verfahren zur herstellung von tetrazolylbenzopyranen
Deady et al. Nucleophilic-Substitution Reactions in Benzo [C][1, 8] Naphthyridines
JPH083167A (ja) ピラゾロ〔１，５−ａ〕ピリミジン誘導体
NO863769L (no) Fremgangsmaate for fremstilling av 4-hydroksy-2-oksopyrrolin-1-yl-acetamid.
Bossio et al. Studies on Isocyanides and Related Compounds. Synthesis of 3‐Substituted 2‐Arylsulfonylamino‐3, 4‐dihydro‐4‐oxoquinazolines via a Novel Three‐Component Reaction
US5536717A (en) 7-[4-(substituted amino)-2-butynl]benzo[B]pyrrolo[3,2,1-JK]-[1,4]benzodiazepin-6-ones
CA3226626A1 (en) Crystal form of compound represented by formula i, and preparation therefor and application thereof
EP1642900A1 (de) Als neue kristalline substanz hergestelltes tricyclisches triazolobenzazepinderivat
IE57877B1 (en) Pyrrolo(3,2,1-hi)indole derivatives,their preparation and pharmaceutical compositions containing them
KR810001451B1 (ko) 피리도 벤조디아제피논의 제조방법
Ferreira et al. Routes to HIV-integrase inhibitors: efficient synthesis of bicyclic pyrimidones by ring expansion or amination at a benzylic position

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050103

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SANDOZ AG

DAX Request for extension of the european patent (deleted)
TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

17Q First examination report despatched

Effective date: 20071218

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 60336226

Country of ref document: DE

Date of ref document: 20110414

Kind code of ref document: P

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 60336226

Country of ref document: DE

Effective date: 20110414

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20110302

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110302

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110613

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110603

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110302

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110302

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110602

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110302

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110302

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110302

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110302

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110704

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110302

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110302

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110302

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110531

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110531

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110531

26N No opposition filed

Effective date: 20111205

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20120131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110302

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 60336226

Country of ref document: DE

Effective date: 20111205

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110531

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110530

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110302

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110530

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110302

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110302

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20160525

Year of fee payment: 14

Ref country code: DE

Payment date: 20160524

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SI

Payment date: 20160420

Year of fee payment: 14

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 60336226

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20170530

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170531

REG Reference to a national code

Ref country code: SI

Ref legal event code: KO00

Effective date: 20180111

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170530

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171201